Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03132454 | Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia | active not recruiting | Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06892158 | Massage Impact on Sleep in Pediatric Oncology | recruiting | N/A | 70 | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07500753 |
| A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients |
| recruiting |
| N/A |
| 30 |
| The First Affiliated Hospital of Soochow UniversityOTHER |
| 1 |
| Apr 15, 2026 |
| clinicaltrials |
| NCT07517315 | Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments | temporarily not available | — | — | Sun Pharma Advanced Research Company LimitedINDUSTRY | 7 | Apr 15, 2026 | clinicaltrials |
| NCT03192397 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06561152 | Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML | recruiting | Phase 1 / Phase 2 | 20 | Stanford UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01890486 | The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | recruiting | — | 2,000 | Wake Forest University Health SciencesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05554419 | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) | not yet recruiting | Phase 2 | 184 | National Cancer Institute (NCI)NIH | 0 | Apr 13, 2026 | clinicaltrials |
| NCT05732103 | A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes | recruiting | Phase 1 / Phase 2 | 225 | Chordia Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06047886 | UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy | recruiting | Phase 1 | 50 | University of Alabama at BirminghamOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06146257 | A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes | recruiting | Phase 1 | 48 | GluBio Therapeutics Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07469046 | VAH vs VA in Newly Diagnosed Elderly AML | not yet recruiting | Phase 3 | 308 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03466294 | Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML | completed | Phase 2 | 42 | University of Colorado, DenverOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07518940 | ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia(ENERGIA) | not yet recruiting | N/A | 25 | Carmen FavaOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07521124 | ABC Maintenance Therapy for AML(ABC-Maint) | not yet recruiting | N/A | 104 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04102020 | A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy(VIALE-M) | completed | Phase 3 | 112 | AbbVieINDUSTRY | 19 | Apr 8, 2026 | clinicaltrials |
| NCT05014165 | Backtracking Leukemia-Typical Somatic Mutations in Cord Blood | recruiting | — | 300 | Children's Oncology GroupNETWORK | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06419634 | Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 105 | Bristol-Myers SquibbINDUSTRY | 4 | Apr 8, 2026 | clinicaltrials |
| NCT07516353 | my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults | not yet recruiting | N/A | 143 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07514832 | VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial | recruiting | Phase 2 | 48 | Beijing 302 HospitalOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03310918 | A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy | active not recruiting | N/A | 320 | Massachusetts General HospitalOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05263271 | Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome | terminated | Phase 1 | 58 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05735717 | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | recruiting | Phase 2 | 70 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05972577 | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | completed | N/A | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511062 | Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML | not yet recruiting | Phase 1 | 32 | Northside Hospital, Inc.OTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07512700 | Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia | recruiting | Phase 2 | 204 | Chinese PLA General HospitalOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT01366612 | Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation(FLUBUTBI) | terminated | Phase 3 | 53 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02204085 | A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 33 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06492304 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 / Phase 2 | 12 | CRISPR TherapeuticsINDUSTRY | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03610971 | Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors | active not recruiting | Phase 2 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06368414 | A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia(AsterA) | recruiting | Phase 2 | 69 | Korean Society of HematologyNETWORK | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07507825 | Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)(VHAG) | not yet recruiting | Phase 2 | 61 | First People's Hospital of HangzhouOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03793478 | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | active not recruiting | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 10 | Apr 1, 2026 | clinicaltrials |
| NCT05304377 | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia(CML) | recruiting | Phase 1 | 250 | Enliven TherapeuticsINDUSTRY | 14 | Apr 1, 2026 | clinicaltrials |
| NCT06279572 | Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy | recruiting | — | 80 | Mayo ClinicOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06660368 | BCL2i CLAG-M in R/R Acute Myeloid Leukemia | recruiting | Phase 2 | 52 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07505160 | Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients | not yet recruiting | Phase 2 | 35 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04716452 | Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia(KNAN2001) | recruiting | Phase 1 | 15 | Keystone Nano, IncINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04745676 | A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome(SICG) | completed | N/A | 36 | University of RochesterOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07503730 | Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).(EARLY-RIF APL) | recruiting | Phase 3 | 224 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02333162 | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | suspended | Phase 1 | 30 | University of ChicagoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03150004 | Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 53 | Medical College of WisconsinOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05933070 | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML(LAUREL) | terminated | Phase 1 | 2 | Inmune Bio, Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT06563804 | A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML | terminated | Phase 1 / Phase 2 | 13 | Servier Bio-Innovation LLCINDUSTRY | 6 | Mar 30, 2026 | clinicaltrials |
| NCT07500441 | Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML | recruiting | — | 100 | Peking University People's HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03286530 | Ruxolitinib + Allogeneic Stem Cell Transplantation in AML | active not recruiting | Phase 2 | 64 | Massachusetts General HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05260528 | CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics(ALFA2101) | recruiting | Phase 2 | 248 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT00819546 | RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS | active not recruiting | Phase 1 | 29 | Richard Stone, MDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03533816 | Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | recruiting | Phase 1 | 38 | University of Kansas Medical CenterOTHER | 1 | Mar 25, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 15, 2026source: clinicaltrials